Looking For Growth, Income, and Stability? This Stock Could Offer All 3

Amgen is presented as a well-rounded investment option combining growth, income, and stability. The biotech giant posted 10% year-over-year revenue growth to $10.1 billion in Q2, with 22 products delivering double-digit sales growth. Despite upcoming patent cliffs for older drugs like Otezla and Enbrel, newer therapies like Tezspire, Tepezza, and Imdelltra are driving growth. The company demonstrated resilience during market downturns and maintains a strong dividend program with 152% growth over the past decade and a 2.3% forward yield.